Evaluation of a New Heparin Agent in Percutaneous Coronary Intervention: Results of the Phase 2 Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial

Circulation - United States
doi 10.1161/circulationaha.109.913277
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention: Arixtra Study in Percutaneous Coronary Intervention: A Randomized Evaluation (ASPIRE) Pilot Trial

Circulation
Cardiovascular MedicinePhysiologyCardiology
2005English

Percutaneous Coronary Intervention

2012English

Percutaneous Coronary Intervention

2007English

Updates in Percutaneous Coronary Intervention

Interventional Cardiology Clinics
Cardiovascular MedicineCardiology
2019English

Percutaneous Coronary Intervention (PCI)

British Journal of Cardiac Nursing
2015English

Bioresorbable Scaffolds: A New Paradigm in Percutaneous Coronary Intervention

BMC Cardiovascular Disorders
Cardiovascular MedicineCardiology
2016English

Diurnal Variation in Outcomes of Percutaneous Coronary Intervention

Cureus
2020English

Percutaneous Coronary Intervention for Stable Coronary Artery Disease

Heart
Cardiovascular MedicineCardiology
2018English

A Percutaneous Coronary Intervention Lab in Every Hospital?

Circulation. Cardiovascular quality and outcomes
MedicineCardiovascular MedicineCardiology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy